Month: November 2022

On February 18, 2021, Rousselot, Philippe published an article.COA of Formula: C26H29Cl2N5O3 The title of the article was BiTtEn by Src inhibitors. And the article contained the following:

One ongoing study from the GIMEMA reported the sequential use of dasatinib and blinatumomab as first-line induction and consolidation therapy in Ph1 ALL patients. The complete mol. response rate was up to 60%.5 A few studies reported on the clin. efficacy of TKIs given in combination with blinatumomab. Assi et al reported a retrospective anal. of 12 patients (9 patients with Ph1 ALL including 5 overt relapses and 4 pos. MRD plus 3 chronic myeloid leukemia blast crisis patients including 1 overt relapse and 2 pos. MRD) treated with blinatumomab and ponatinib (n = 8), dasatinib (n = 3), or bosutinib (n = 1). The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).COA of Formula: C26H29Cl2N5O3

The Article related to blinatumomab lymphoblastic leukemia tyrosine kinase src inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.COA of Formula: C26H29Cl2N5O3

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Iurlo, Alessandra; Cattaneo, Daniele; Malato, Alessandra; Accurso, Vincenzo; Annunziata, Mario; Gozzini, Antonella; Scortechini, Anna Rita; Bucelli, Cristina; Scalzulli, Emilia; Attolico, Imma; Maggi, Alessandro; Martino, Bruno; Caocci, Giovanni; Abruzzese, Elisabetta; Pregno, Patrizia; Luciano, Luigiana; Breccia, Massimo published an article in 2020, the title of the article was Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.SDS of cas: 380843-75-4 And the article contains the following content:

Ponatinib is a potent, orally available, third-generation tyrosine kinase inhibitor (TKI) with proven efficacy in both mutated and unmutated BCR-ABL1-pos. chronic myeloid leukemia (CML) patients including the gatekeeper T315I mutation. While its efficacy has been firstly confirmed in the pivotal phase II PACE trial, nevertheless, when used at the recommended starting dose of 45 mg/d ponatinib raised some concerns due to an increased risk of cardiovascular (CV) adverse events (AEs). In fact, when assessed in a hind limb ischemia model, owing to its multikinase inhibitory properties ponatinib may cause endothelial dysfunction. Ponatinib may affect targets such as VEGFR and promote the expression of proatherogenic surface adhesion receptors. Since these effects were found to be dose-related, suggesting a direct relationship between CV AEs and ponatinib dosage, a reduction of the daily dose has been advised for patients who already achieved at least a major cytogenetic response (MCyR). The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).SDS of cas: 380843-75-4

The Article related to ponatinib chronic myeloid leukemia patient tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.SDS of cas: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Ha, Y. N. E.; Dai, Y.; Wufuer, D.; Pidayi, M.; Anasihan, G.; Chen, L. published an article in 2020, the title of the article was Second-generation Src/Abl inhibitor bosutinib effectively induces apoptosis in human esophageal squamous cell carcinoma (ESCC) cells via inhibiting Src/Abl signaling.Computed Properties of 380843-75-4 And the article contains the following content:

Esophageal cancer is a prevalent type of cancer worldwide and is ranked sixth among cancer-associated mortalities. Aberrant activation of the non-receptor tyrosine kinase Src and c-Abl contribute to the progression of ESCC. Thus, targeting these kinases to treat ESCC is a promising strategy. In this paper, we report that the potent dual Src/Abl inhibitor bosutinib exerts anti-tumor effects on ESCC. Bosutinib inhibits ESCC cell proliferation in a dose-dependent manner. Furthermore, bosutinib suppresses the colony formation ability of ESCC cells. Mechanistically, bosutinib effectively inhibits c-Abl and Src and its downstream signaling pathways, PI3K/AKT/mTOR and JAK/STAT3. In addition, bosutinib enhances the cytotoxic effects of doxorubicin on ESCC cells. In summary, our results reveal that Src and Abl are potential therapeutic targets in ESCC and that the novel Src/Abl inhibitor bosutinib alone or in combination with other chemotherapeutic agents may be a viable option for treating ESCC patients. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Computed Properties of 380843-75-4

The Article related to src abl bosutinib human esophageal squamous cell carcinoma signaling, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Computed Properties of 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 31, 2022, Bruemmendorf, Tim H.; Cortes, Jorge E.; Milojkovic, Dragana; Gambacorti-Passerini, Carlo; Clark, Richard E.; le Coutre, Philipp; Garcia-Gutierrez, Valentin; Chuah, Charles; Kota, Vamsi; Lipton, Jeffrey H.; Rousselot, Philippe; Mauro, Michael J.; Hochhaus, Andreas; Hurtado Monroy, Rafael; Leip, Eric; Purcell, Simon; Yver, Anne; Viqueira, Andrea; Deininger, Michael W.; BFORE study investigators published an article.Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. And the article contained the following:

This anal. from the multicenter, open-label, phase 3 BFORE trial reports efficacy and safety of bosutinib in patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) after five year’s follow-up. Patients were randomized to 400-mg once-daily bosutinib (n = 268) or imatinib (n = 268; three untreated). At study completion, 59.7% of bosutinib- and 58.1% of imatinib-treated patients remained on study treatment. Median duration of treatment and time on study was 55 mo in both groups. Cumulative major mol. response (MMR) rate by 5 years was higher with bosutinib vs. imatinib (73.9% vs. 64.6%; odds ratio, 1.57 [95% CI, 1.08-2.28]), as were cumulative MR4 (58.2% vs. 48.1%; 1.50 [1.07-2.12]) and MR4.5 (47.4% vs. 36.6%; 1.57 [1.11-2.22]) rates. Superior MR with bosutinib vs. imatinib was consistent across Sokal risk groups, with greatest benefit seen in patients with high risk. Treatment-emergent adverse events (TEAEs) were consistent with 12-mo data. After 5 years of follow-up there was an increase in the incidence of cardiac, effusion, renal, and vascular TEAEs in bosutinib- and imatinib-treated patients, but overall, no new safety signals were identified. These final results support 400-mg once-daily bosutinib as standard-of-care in patients with newly diagnosed CP CML. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to bosutinib imatinib diagnosed phase chronic myeloid leukemia clin trial, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Shahar, Or David; Kalousi, Alkmini; Eini, Lital; Fisher, Benoit; Weiss, Amelie; Darr, Jonatan; Mazina, Olga; Bramson, Shay; Kupiec, Martin; Eden, Amir; Meshorer, Eran; Mazin, Alexander V.; Brino, Laurent; Goldberg, Michal; Soutoglou, Evi published an article in 2014, the title of the article was A high-throughput chemical screen with FDA approved drugs reveals that the antihypertensive drug Spironolactone impairs cancer cell survival by inhibiting homology directed repair.HPLC of Formula: 86393-32-0 And the article contains the following content:

DNA double-strand breaks (DSBs) are the most severe type of DNA damage. DSBs are repaired by non-homologous end-joining or homol. directed repair (HDR). Identifying novel small mols. that affect HDR is of great importance both for research use and therapy. Mols. that elevate HDR may improve gene targeting, whereas inhibiting mols. can be used for chemotherapy, since some of the cancers are more sensitive to repair impairment. Here, the authors performed a high-throughput chem. screen for FDA approved drugs, which affect HDR in cancer cells. The authors found that HDR frequencies are increased by retinoic acid and Idoxuridine and reduced by the antihypertensive drug Spironolactone. The authors further revealed that Spironolactone impairs Rad51 foci formation, sensitizes cancer cells to DNA damaging agents, to Poly (ADP-ribose) polymerase (PARP) inhibitors and crosslinking agents and inhibits tumor growth in xenografts, in mice. This study suggests Spironolactone as a new candidate for chemotherapy. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).HPLC of Formula: 86393-32-0

The Article related to throughput screen antitumor neoplasm spironolactone homol directed repair, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.HPLC of Formula: 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2022, Gambacorti-Passerini, Carlo; Nicolini, Franck Emmanuel; Larson, Richard A.; Aroldi, Andrea; Fontana, Diletta; Piazza, Rocco; le Coutre, Philipp; Antolini, Laura; Assouline, Sarit published an article.Computed Properties of 380843-75-4 The title of the article was Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. And the article contained the following:

Rates of 142 nominal disease categories were significantly increased in CML patients vs. the general population, even after excluding the initial 6 mo of treatment, when factors associated with the presence of uncontrolled leukemia could be involved in generating the reported abnormalities. Based on these data our general policy for CML patients is to actively look for early diagnosis of second cancers. Whether this result derives from increased susceptibility, increased monitoring of patients or both,it remains to be established. This could be linked to the preferential inhibition of PDGFR over ABL1 operated by imatinib. A second important aspect of this paper relates to the use of second generation TKI (2GEN). This was particularly evident for nilotinib and dasatinib, for which sufficient data were available, while insufficient data were present regarding the use of bosutinib and ponatinib. Not surprisingly, Nilotinib resulted in an increased risk of cardiovascular events and diabetes development, while dasatinib use showed increased risks of pleural effusions and infections. Since CML patients may be taking these TKIs for many years, it is in cumbent on physicians to manage and minimize treatment-related risks and co-morbid conditions. In conclusion,the report is important issue in the management of CML: when a normal life expectancy is the goal of the therapy, the safety of the choosen TKI becomes of paramount importance, especially for first line therapy. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Computed Properties of 380843-75-4

The Article related to human chronic myeloid leukemia cardiovascular disease tki dasatinib safety, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Computed Properties of 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 31, 2022, Haddad, Fadi G.; Sasaki, Koji; Issa, Ghayas C.; Garcia-Manero, Guillermo; Ravandi, Farhad; Kadia, Tapan; Cortes, Jorge; Konopleva, Marina; Pemmaraju, Naveen; Alvarado, Yesid; Yilmaz, Musa; Borthakur, Gautam; DiNardo, Courtney; Jain, Nitin; Daver, Naval; Short, Nicholas J.; Jabbour, Elias; Kantarjian, Hagop published an article.SDS of cas: 380843-75-4 The title of the article was Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. And the article contained the following:

Tyrosine kinase inhibitors (TKIs) discontinuation in patients with Philadelphia-chromosome-pos. chronic myeloid leukemia (Ph-pos. CML) is increasingly considered. We aim to evaluate the outcome of patients with CML who discontinued TKIs, and determine the factors associated with differences in the success rates of treatment-free remission (TFR). Patients with Ph-pos. CML treated between Oct. 1999 and Feb. 2017 who discontinued therapy were analyzed. A major mol. response (MMR) was defined as BCR-ABL1/ABL1 ratio on the International Scale ≤0.1%. TFR failure was defined as the loss of MMR on any single test. We analyzed TFR rates according to duration and depth of response, and conducted a multivariate anal. for factors associated with loss of MMR. Two-hundred and eighty-four patients were analyzed; 199 patients (70%) electively discontinued TKIs. At a median follow-up of 36 mo (95% confidence interval, 32-40) after TKI discontinuation, 53 patients (19%) lost MMR. The estimated 5-yr TFR rate was 79%. All but one patient regained MMR after resuming therapy. The estimated 5-yr TFR rates were higher with MR4 and MR4.5 ≥5 years, compared with MR4 <5 years (87% vs. 92% vs. 64%; p < .0001). By multivariate anal., only the duration of MR4 or MR4.5 ≥5 years before stopping treatment was associated with a lower risk of loss of MMR. In summary, TFR is safe and feasible in patients with Ph-pos. CML on TKI therapy. Achieving MR4 or MR4.5 for at least 5 years is correlated with a better outcome. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).SDS of cas: 380843-75-4

The Article related to chronic myeloid leukemia tyrosine kinase inhibitor treatment free remission, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.SDS of cas: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On June 30, 2021, Is, Yusuf Serhat published an article.Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Elucidation of Ligand/Protein Interactions between BCR-ABL Tyrosine Kinase and Some Commercial Anticancer Drugs Via DFT Methods. And the article contained the following:

In this study, the interactions of 7 com. available BCR-ABL tyrosine kinase enzyme inhibitors with amino acids in the active site of the relevant enzyme were investigated quantum mech. Here a per-residue study was carried out. Interaction energies were calculated by using the coordinates of the critical residues in the binding site of the enzyme and the drug mols. docked in this region. DFT methods were used during the QM processes. All interaction energies were calculated via M06-2X functional and 6-31G (d,p) basis set in vacuum. Based on the results obtained, it was tried to be determined which of the important residues in the binding cavity of the enzyme could better interact with the examined ligands. It is thought that this study may contribute to the development of tyrosine kinase enzyme inhibitors. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to tyrosine kinase anticancer drugs ligand protein interaction density function, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 1, 2021, Hall, Kevin H.; Brooks, Angelique; Waller, Edmund K. published an article.Recommanded Product: 380843-75-4 The title of the article was Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib. And the article contained the following:

A case of 43-yr-old female was diagnosed with chronic myeloid leukemia in chronic phase (CML-CP) in 2001 when she presented with leukocytosis and a subsequent bone marrow biopsy confirmed the presence of BCR-ABL1 t(9;22) fusion oncogene is reported. As the patient had previously failed all other available TKIs, approval was obtained for use of asciminib through compassionate use. The patient stopped bosutinib and started asciminib 40 mg twice daily based on phase I single agent data in Apr. 2020. Unfortunately, her quant. BCR-ABL1 transcript continued to rise, and bosutinib 500 mg daily was resumed in addition to asciminib in August 2020 when her BCR-ABL1 transcript was 54.6%. Her transcript peaked 2 wk later at 95% but dramatically declined down to 0.1% within 3 mo of starting the combination. She has now continued combination therapy with bosutinib and asciminib for more than 8 mo to date with no discernable side effects. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 380843-75-4

The Article related to asciminib bosutinib anticancer combination bcr abl1 chronic myeloid leukemia, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Sunagar, Manjunath G.; Gaonkar, Supreet; Sunagar, Santosh G.; Deshapande, Narahari; Belavagi, Ningaraddi S.; Khazi, Imtiyaz Ahmed M. published an article in 2016, the title of the article was Synthesis of novel N-9 substituted 6-(4-(4-propoxyphenyl)piperazin-1-yl)-9H-purine derivatives as inducers of apoptosis in MCF-7 breast cancer cells.Application of 67914-60-7 And the article contains the following content:

A series of N-9 substituted 6-(4-(4-propoxyphenyl)piperazin-1-yl)-9H-purine derivatives (PP05-PP21) were prepared and evaluated for their anticancer activity against a panel of human cancer cell lines. Evaluation of results revealed that some of the synthesized compounds exhibited promising anticancer activity against the examined cancer cell lines. The structure-activity relationship (SAR) studies in the present work revealed that simple N-9 alkyl substituted 6-(4-(4-propoxyphenyl)piperazin-1-yl)-9H-purines are potent anticancer agents. Among all the compounds, PP17 (9-sec-butyl-6-(4-(4-propoxyphenyl)piperazin-1-yl)-9H-purine) showed good inhibitory activity against MCF-7 cells. Cell cycle anal. of the compound suggested that induces G2/M phase arrest. Biochem. experiments showed that PP17 significantly induced MCF-7 cell apoptosis. Therefore, compound PP17 with a potent in vitro anticancer activity can serve as a promising lead compound for further study. The experimental process involved the reaction of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone(cas: 67914-60-7).Application of 67914-60-7

The Article related to anticancer agent apoptosis breast cancer cell structure activity relationship, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Application of 67914-60-7

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics